Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html Government Agencies and Related Announcements Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) Our Team Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy Basic Cancer Immunology for Clinicians A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML TTCI at a glance Chiang Mai University Team Mahidol University Team AP-SciBio 2027 x WIC APAC 2027 & Thai Immunology Annual Meeting CAR T-cell Immunometabolism: Insights from Patients Member Contents TTCI to Participate in WIC-APAC 2026 NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 White Paper Efficiently targeting folate receptor alpha-positive ovarian cancer by human antibody VH domain-based chimeric antigen receptor (CAR) Thai Immunology Annual Meeting 2026 IMMUNOLOGY SEMINAR: PEPTIDE CANCER VACCINE EXPERIENCE AT NCI Enhancing T cell cytotoxicity against lung cancer with an αPD-L1 protein engager and gemcitabine combination therapy Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy Pediatric Neuro-Oncology Consortium – Chulalongkorn University Research Forum Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) CAR T-cell therapy for paediatric solid tumours: clinical trial development and preclinical modelling IPOPI | SEAPID | Chulalongkorn | Erasmus MC Meeting 2026 University of Wisconsin School of Medicine and Public Health A multi-center clinical research project to study the Safety and Efficacy of CD19 CAR T-cells in ALL (Acute Lymphoblastic Leukemia) by Academic Hubs Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody TTCI Webinar “CAR T-cell Immunometabolism, Insights from Patients” Patient Care and Toxicities Management of CAR T-cell in Pediatrics TTCI Members Receive Research Recognition Awards from Faculty of Sciences, Chiang Mai University New Immune Cell Engager Combined with Chemotherapy Boosts Attack on Multiple Myeloma Celebrating Excellence in Immunotherapy: Dr. Piriya Luangwattananun Honored as Young Investigator Equipment Chulalongkorn University Team Researchers Develop Method to Remove Specific Problematic Proteins for Improved Drug Effects Khonkaen University Team Enhancing Innate and Adaptive Immunity to Combat Multiple Myeloma: Combined Use of Trispecific NK Cell Engagers (TriKEs) and Bispecific T-Cell Engagers (BiTEs) in Immunotherapy New Dual-Targeting Protein and Chemotherapy Boost T-Cell Attack on Lung Cancer Vaccine and Therapeutic RNA Research Forum 2025 Announcement: Student Progress Report 1/2025 Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody Special Lecture: Advanced Cellular Therapeutics for Hematologic Malignancies Chula Licenses Thai PD-1 Antibody to US Biopharma นวัตกรรมเซลล์บำบัดมะเร็ง “CAR-T cell” โอกาสใหม่ของผู้ป่วยมะเร็งไทย International Collaborator TTCI Welcomes World-Class Expert for Special Lecture and Advisory Role TTCI Representatives Join World Immunotherapy Council Asia Pacific (WIC APAC 2025) in Singapore Thammasat University Team